What drives us is the realization that there is still a lot to be gained in the treatment of cancer. Not only in terms of survival, but also in the quality of life of people living with cancer. DCprime aims to make a meaningful contribution to the field of immuno-oncology by developing relapse vaccines and by continuing to invest in a broad cancer immunology research network.

Our management

Erik Manting, PhD
Chief Executive Officer
Read more.

 

 

Jeroen Rovers, MD PhD
Chief Medical Officer
Read more.

 

 

 

Our supervisory board

Dharminder Chahal
chairman of the Supervisory Board
Read more.

 

 

 

andrea van elsas, PHD
Supervisory Board member
Read more.

 

 

hans preusting, PHD MBA
Supervisory Board member
Read more.

 

 

Our investors

Van Herk Groep is the collective name for the businesses and companies belonging to the Van Herk family of Rotterdam. Van Herk Groep was founded by Aat van Herk (1951). Van Herk Ventures invests in the life sciences sector through direct investments in private and listed companies and in venture capital funds. For listed companies, Van Herk invests globally while focusing on the Benelux countries for private companies and venture capital funds.